ClinicalTrials.gg

Program

astegolimab

Also written as “Astegolimab”, “MSTT1041A” and “AMG 282”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma · Dermatitis, Atopic · COVID-19 · Nasal Polyps, led by 2 companies.

Furthest: phase 3, since Oct 24, 20229 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche71 open or runningphase 3since Oct 24, 2022Sep 27, 2016Jun 30, 2027phase 3 · NCT05878769
Amgen20 open or runningphase 1since Aug 21, 2013Aug 21, 2013none ahead
  • Named in Hoffmann-La Roche’s own pipeline as RG6149 astegolimab, phase 3, as of Oct 22, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2013First study: phase 1 study in AsthmaNew to AmgenAmgen · NCT01928368 · 70 enrolled · United States
  2. Jun 19, 2014Phase 1 study in Chronic Rhinosinusitis With Nasal PolypsAmgen · NCT02170337 · 41 enrolled · United States
  3. Sep 27, 2016Hoffmann-La Roche's first study: phase 2 study in AsthmaNew to Hoffmann-La RocheHoffmann-La Roche · NCT02918019 · 517 enrolled · United States, Argentina, Belgium and more
  4. Nov 16, 2018Phase 2 study in Dermatitis, AtopicHoffmann-La Roche · NCT03747575 · 65 enrolled · United States, Germany, Poland
  5. May 11, 2020Phase 2 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04386616 · 396 enrolled · United States, Brazil, Mexico and more
  6. Aug 31, 2021Phase 2 study in Pulmonary Disease, Chronic ObstructiveHoffmann-La Roche · NCT05037929 · 1,334 enrolled · United States, Argentina, Australia and more
  7. Oct 24, 2022Phase 3 study in Pulmonary Disease, Chronic ObstructiveHoffmann-La Roche · NCT05595642 · 1,380 enrolled · United States, Argentina, Australia and more
  8. May 19, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveHoffmann-La Roche · NCT05878769 · 2,000 enrolled · United States, Argentina, Australia and more
  9. Jun 12, 2024Phase 1 study in Healthy VolunteersHoffmann-La Roche · NCT06462118 · 78 enrolled · United States

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveHoffmann-La Roche · NCT05878769

TargetBeta

“A human monoclonal antibody directed against ST2, a receptor for the human inflammatory cytokine interleukin-33 (IL-33), with potential anti-inflammatory activity. Upon administration, astegolimab targets and binds to ST2. This prevents the binding of IL-33 to its receptor complex ST2 (IL1RL1) an…”NCIt, read by Claude

Other programs on IL33R

ProgramCompanyFurthest phaseStudies
TQC2938Sino Biopharmaceuticalphase 23

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06462118Healthy Volunteers · United States1CompletedHoffmann-La RocheOct 22, 202478
NCT05878769Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3Active, not recruitingHoffmann-La RocheJun 30, 20272,000
NCT05595642Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedHoffmann-La RocheJun 24, 20251,380
NCT05037929Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more2CompletedHoffmann-La RocheFeb 24, 20251,334
NCT04386616COVID-19 Pneumonia · United States, Brazil, Mexico and more2CompletedHoffmann-La RocheJan 8, 2021396
NCT03747575Dermatitis, Atopic · United States, Germany, Poland2CompletedHoffmann-La RocheMar 11, 202065
NCT02918019Asthma · United States, Argentina, Belgium and more2CompletedHoffmann-La RocheApr 5, 2019517
NCT02170337Chronic Rhinosinusitis With Nasal Polyps · United States1CompletedAmgenMay 201641
NCT01928368Asthma · United States1CompletedAmgenMar 201670

How it is read

Names in the registry

  • “Astegolimab”, 4 entries
  • “MSTT1041A”, 3 entries
  • “AMG 282”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.